Skip to Content

AML: Blocking the IL1-IL1RAP signaling axis might promote normal hematopoietic recovery after chemotherapy

In this MEDtalk Bauke de Boer, Biotech Research & Innovation Centre, University of Copenhagen, explains the role of IL1-IL1RAP axis in the development of AML, and why blocking the effect of the IL1-IL1RAP signaling axis with Anakinra, a IL1 receptor.

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top